ATE394121T1 - Verwendung von antikörpern gegen das muc18- antigen - Google Patents

Verwendung von antikörpern gegen das muc18- antigen

Info

Publication number
ATE394121T1
ATE394121T1 AT02797517T AT02797517T ATE394121T1 AT E394121 T1 ATE394121 T1 AT E394121T1 AT 02797517 T AT02797517 T AT 02797517T AT 02797517 T AT02797517 T AT 02797517T AT E394121 T1 ATE394121 T1 AT E394121T1
Authority
AT
Austria
Prior art keywords
muc18
antibodies against
muc18 antigen
antigen
antibodies
Prior art date
Application number
AT02797517T
Other languages
English (en)
Inventor
Menashe Bar-Eli
Larry L Green
Original Assignee
Amgen Fremont Inc
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Fremont Inc, Univ Texas filed Critical Amgen Fremont Inc
Application granted granted Critical
Publication of ATE394121T1 publication Critical patent/ATE394121T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1066—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02797517T 2001-12-28 2002-12-26 Verwendung von antikörpern gegen das muc18- antigen ATE394121T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34646001P 2001-12-28 2001-12-28

Publications (1)

Publication Number Publication Date
ATE394121T1 true ATE394121T1 (de) 2008-05-15

Family

ID=23359486

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02797517T ATE394121T1 (de) 2001-12-28 2002-12-26 Verwendung von antikörpern gegen das muc18- antigen

Country Status (9)

Country Link
US (2) US7090844B2 (de)
EP (1) EP1467757B1 (de)
JP (1) JP2005514409A (de)
AT (1) ATE394121T1 (de)
AU (1) AU2002361887A1 (de)
CA (1) CA2472154A1 (de)
DE (1) DE60226499D1 (de)
ES (1) ES2307824T3 (de)
WO (1) WO2003057006A2 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2441953A1 (en) * 2001-03-23 2002-10-03 The Board Of Regents Of The University Of Texas System Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-il8 and anti-muc18 in diverse types of tumors
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
EP1467756A4 (de) 2001-12-28 2007-03-21 Abgenix Inc Verfahren zur verwendung von anti-muc18-antikörpern
EP1470146B8 (de) * 2001-12-28 2007-09-12 Amgen Fremont Inc. Antikörper gegen das muc18-antigen
JP2005514409A (ja) 2001-12-28 2005-05-19 アブジェニックス・インコーポレーテッド Ｍｕｃ１８抗原に対する抗体の使用
US20060034952A1 (en) * 2004-08-13 2006-02-16 Kondhalkar Mrinmayee B Agent for inhibiting the growth of mammalian hair
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
CA2729403A1 (en) * 2008-06-30 2010-01-07 Oncotherapy Science, Inc. Anti-cdh3 antibodies labeled with radioisotope label and uses thereof
US8293468B2 (en) * 2009-06-10 2012-10-23 Centre Hospitalier De L'université De Montréal MCAM modulation and uses thereof
NO2535358T3 (de) * 2010-02-10 2018-05-19
WO2012170071A1 (en) * 2011-06-06 2012-12-13 Elan Pharmaceuticas, Inc Mcam antagonists and methods of treatment
TWI595007B (zh) * 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗ｍｃａｍ抗體及相關使用方法
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
EP3712166A1 (de) 2013-09-05 2020-09-23 Amgen Inc. Fc-haltige moleküle mit vorhersagbaren, konsistenten und reproduzierbaren glycoformprofilen
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
PT3116911T (pt) 2014-03-12 2019-09-04 Prothena Biosciences Ltd Anticorpos anti-mcam e métodos de utilização associados
WO2015136472A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
WO2015175861A1 (en) 2014-05-16 2015-11-19 Amgen Inc. Assay for detecting th1 and th2 cell populations
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046776A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
AU2016361462B2 (en) 2015-11-27 2023-09-21 Csl Limited CD131 binding proteins and uses thereof
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
AU2018235928B2 (en) 2017-03-14 2023-09-21 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
US11427648B2 (en) 2017-10-06 2022-08-30 Universite D'aix-Marseille Anti-CD146 antibodies and uses thereof
US12325737B2 (en) 2018-03-26 2025-06-10 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
KR20220069982A (ko) 2019-09-26 2022-05-27 암젠 인크 항체 조성물의 생산 방법
EP4045515A4 (de) 2019-10-18 2023-10-18 The Regents Of The University Of Michigan Biomaterialsensorsysteme
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
US20240043501A1 (en) 2020-10-15 2024-02-08 Amgen Inc. Relative unpaired glycans in antibody production methods
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
JP2024537100A (ja) 2021-10-05 2024-10-10 アムジエン・インコーポレーテツド Ｆｃガンマ受容体ＩＩ結合、及びグリカン含量
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
EP4602174A1 (de) 2022-10-13 2025-08-20 Sana Biotechnology, Inc. Auf hämatopoetische stammzellen abzielende virale partikel
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
JP2026516670A (ja) 2023-04-20 2026-05-26 アムジエン・インコーポレーテツド 相対的な不対グリカン含有量を決定する方法
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
AU2024325342A1 (en) 2023-08-14 2026-02-26 Amgen Inc. Methods for reducing yellow color
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods
WO2026090253A1 (en) 2024-10-23 2026-04-30 Amgen Inc. Methods of determining glycan pairing content

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US68319A (en) * 1867-08-27 Charles f
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
US5800820A (en) 1989-01-10 1998-09-01 Repligen Corporation Methods and compositions for treatment of angiogenic diseases
CA2065299C (en) 1989-08-09 2001-07-24 Buck A. Rhodes Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5697901A (en) 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (de) * 1990-01-12 2008-07-30 Abgenix, Inc. Bildung von xenogenen Antikörpern
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US6048972A (en) 1994-07-13 2000-04-11 Chugai Pharmaceutical Co., Ltd. Recombinant materials for producing humanized anti-IL-8 antibodies
EP1972194A1 (de) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgene Säugetiere mit menschlichen IG-Orten mit mehreren VH- und VK-Regionen und darin erzeugten Antikörpern
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
IL121440A0 (en) 1997-07-31 1998-01-04 Yeda Res & Dev The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in photodynamic therapy and certain such novel derivatives
US6342220B1 (en) * 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
EP1179541B1 (de) 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Zusammensetzungen und Verfahren zur Krebsbehandlung durch die selektive Hemmung von VEGF
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
CA2441953A1 (en) 2001-03-23 2002-10-03 The Board Of Regents Of The University Of Texas System Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-il8 and anti-muc18 in diverse types of tumors
JP2005514409A (ja) 2001-12-28 2005-05-19 アブジェニックス・インコーポレーテッド Ｍｕｃ１８抗原に対する抗体の使用

Also Published As

Publication number Publication date
EP1467757A2 (de) 2004-10-20
AU2002361887A1 (en) 2003-07-24
DE60226499D1 (de) 2008-06-19
EP1467757B1 (de) 2008-05-07
WO2003057006A2 (en) 2003-07-17
ES2307824T3 (es) 2008-12-01
US20040115205A1 (en) 2004-06-17
CA2472154A1 (en) 2003-07-17
US20060246077A1 (en) 2006-11-02
JP2005514409A (ja) 2005-05-19
US7090844B2 (en) 2006-08-15
WO2003057006A3 (en) 2003-09-04
EP1467757A4 (de) 2005-08-17

Similar Documents

Publication Publication Date Title
DE60226499D1 (de) Verwendung von antikörpern gegen das muc18-antigen
DE60220719D1 (de) Antikörper gegen das muc18-antigen
WO2003057837A8 (en) Methods for using anti-muc18 antibodies
BR0011838A (pt) Elementos misturadores estáticos empilhados
MX338122B (es) Epitopes terapeuticos y usos de los mismos.
ATE490275T1 (de) Antikörper gegen interleukin-22 und verwendungen dafür
ATE388167T1 (de) Menschlicher antikörper gegen gangliosid gd3 für die transplantationskomplementarität bestimmente regionund derivate des antikörpers gegen das gangliosid gd3
TNSN05300A1 (en) Treatment with anti-vegf antibodies
BG101024A (bg) Моноклонално антитяло срещу сd44v6
TW200505942A (en) Antibody molecules having specificity for human IL-1β
ATE432986T1 (de) Menschlicher rezeptor für tumor necrosis factor
DE60234269D1 (de) Substituierte aryl 1,4-pyrazin derivate
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
DE69934515D1 (de) Humanisierte monoklonale integrin antikörper
EA200401341A1 (ru) Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания
DK0552296T3 (da) Monoklonale antistoffer fra mus
NO20055741D0 (no) Nye kjemiske forbindelser
EA200100264A1 (ru) Ангиоцидин: адгезионный рецептор опухолей клетки, специфический для cys-ser-val-thr-cys-gly
TR200200278T2 (tr) Kalsilitik bileşimler
NO20026286D0 (no) Nye peptider
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
ATE538376T1 (de) Herstellung polyklonaler, monospezifischer antikörper gegen die upar-varianten del4, del5 und del4+5 sowie deren verwendung für diagnostische und therapeutische zwecke
AU2003225900A1 (en) Antibody disulfide isomers, use thereof, and methods of analyzing same
EA200501259A1 (ru) Комбинированное применение фибрата и орлистата для лечения ожирения

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties